Few London-listed industrials have been rewarded as consistently as Halma, and few have had a summer quite like this one. The group delivered record Revenue and profit in June, then watched its shares suffer their sharpest one-day fall in years. The reason was not what the company had done, but where its growth was coming from and how long that growth could last.

Now Halma (LSE:HLMA), the FTSE 100 safety, environmental and medical technology group, is heading into its half-year trading statement, reported to be due on 24 September 2026. The coming update is the next test of whether the June sell-off went too far.

Sentiment starts to stabilise

After a heavy de-rating, the shares have started to recover some ground, closing at £35.28 on 17 September, and investors are looking to the 24 September statement as the next visible catalyst. Opinion on the stock remains divided, which suggests the market has not settled on how to value the Business after its reset.

Record numbers that still disappointed

The context for all this is Halma's full-year results for the year to March 2026, published on 11 June. Revenue rose 15% to £2,582.3m, with organic growth of 16%. The company said roughly eight percentage points of that organic growth came from an unusually strong performance in its photonics business. Adjusted EBIT climbed 22% to £594.5m, statutory profit before tax rose 27% to £520.7m and adjusted Earnings Per Share increased 21% to 114.05p.

Chief executive Marc Ronchetti said Halma had grown revenue to over £2.5bn and adjusted profit to over £500m, "both for the first time". The total Dividend rose 7% to 24.74p, which the company said marked the 47th consecutive year of increases of 5% or more. Net Debt stood at 1.16 times adjusted EBITDA, up from 0.97 times but well inside Halma's stated operating range of up to two times.

The problem lay in the guidance. For the current year, Halma said it expected low double-digit organic constant currency revenue growth, including a premium of about five percentage points from photonics. It also expected the adjusted EBIT Margin to be in line with 2026, excluding a one-off item. In other words, the photonics contribution was forecast to shrink and margins were not set to expand.

Why photonics became the whole story

The shares fell 15% on 12 June, their biggest one-day fall in years. Sales of light-based products to data centre operators were expected to slow from growth of 52% to about 30%. One hyperscale technology customer now accounts for about 20% of group revenue, up from 15%.

That customer concentration sits uneasily with Halma's long-standing appeal. The group is built as a decentralised collection of dozens of niche businesses across safety, environmental and analysis, and healthcare markets. Investors have paid a premium multiple for that diversity and the steady, compounding returns it has produced through regular bolt-on acquisitions. A single customer driving a fifth of revenue makes the story look more cyclical and more exposed to data centre spending decisions than many shareholders had assumed.

Proportion matters, though. The photonics boom has lifted earnings rather than hurt them, and the rest of the portfolio still sits in markets underpinned by regulation, safety standards and health spending. Halma is widely seen as a well-managed company with a strong track record, although the photonics slowdown offers some reason for caution.

What could still go wrong

The biggest risk is that data centre Demand cools faster than the roughly 30% growth now expected. Hyperscale customers can shift orders, change suppliers or pause projects with little warning, and a business this concentrated is vulnerable to one customer's Capital spending plans. Any hint in the trading statement that photonics momentum is fading ahead of guidance would probably be felt quickly in the share price.

Valuation is a second pressure point. Even after the de-rating, Halma trades at a premium to most UK industrials, which leaves little room for disappointment. Flat margin guidance also removes a lever that has historically supported earnings upgrades. Beyond that, Halma is exposed to the usual industrial risks: currency swings, since much of its revenue is earned outside the UK, softer public-sector and healthcare budgets, and the execution risk that comes with an acquisition-led model. Net debt has risen, so the pace and price of deals will matter.

The dates and details that matter next

The immediate focus is the half-year trading statement. The key questions are whether Halma is on track for low double-digit organic growth, whether the photonics premium is tracking at about five percentage points and whether margins are holding in line with last year. Any comment on the concentration of revenue with the large hyperscale customer, or on how the photonics order book is developing, will be closely read.

Investors will also watch for Acquisition news, since bolt-on deals remain central to how Halma compounds growth. Full half-year results, which Halma has typically published in November, should then give the detailed sector-by-sector breakdown and the interim dividend. How sentiment develops from here is likely to depend on what the trading statement reveals.

Conclusion

Halma enters its trading update from an unusual position: fresh from record results, yet priced for more doubt than at any point in recent years. The recent recovery in the shares suggests some of the pessimism has eased, but it is no guarantee of a rebound. The statement will show whether the June sell-off reflected a lasting change in the growth story or simply a reset of expectations for a business whose core traits of diversity, cash generation and dividend growth remain largely in place.